glp-1 drugs key developments 2025 Receptor Agonist Market Growth Analysis Patients Face New Barriers for
Description
Without taking action, many people eventually develop Type 2 diabetes
and the Hengrui Diabetes Metabolism Research Fund (No
2019;4(12) doi: 10.1172/jci.insight.124819
The review further distinguishes between established outcome benefits (CVD, CKD, and OSA) and conditions still under investigation (neurodegeneration, arthritis, and some liver endpoints)
Jung, G
The MR method showed a significant association between GLP-1RA and reduced risk of DR (OR = 0.59, 95%CI: 0.390.89, P = 0.0109), in addition, similar results were also found with the SMR method (OR = 0.48, 95%CI: 0.270.86, P = 0.0129)
